Jennifer Alexander‑Brett, MD, PhD, Associate Professor of Medicine, has been featured in a recent Nature Biotechnology article highlighting major advances in targeting interleukin‑33 (IL‑33) signaling in chronic obstructive pulmonary disease (COPD). The article, “Newcomer anti‑IL‑33 makes strides in COPD,” underscores the growing impact of IL‑33–focused therapeutics and the importance of foundational biological insight in translating discovery to patient care.
Dr. Alexander‑Brett is recognized in the piece as a physician–scientist whose basic and translational research has helped define IL‑33 as a central regulator of epithelial injury, immune activation, and chronic inflammation in lung disease. Her work has illuminated the complexity of IL‑33 signaling pathways and the critical need to understand the immune “niches” in which these pathways operate. This knowledge is proving essential as IL‑33–targeted therapies advance into late‑stage clinical trials. As noted in the article, Dr. Alexander‑Brett is also involved in ongoing phase 3 clinical studies, reflecting her longstanding commitment to bridging bench science with clinical innovation.
The Nature Biotechnology feature highlights how emerging IL‑33 antibodies may address inflammatory mechanisms that existing COPD therapies do not adequately control, offering renewed hope for patients with limited treatment options. Dr. Alexander‑Brett’s contributions exemplify the scientific rigor and translational focus required to move complex immunologic discoveries toward real‑world impact.
This recognition also reflects the strength of our division’s broader research efforts, which span fundamental immunology, epithelial biology, and precision medicine approaches to pulmonary and inflammatory diseases. Through collaborative, multidisciplinary science, our investigators continue to advance understanding of disease mechanisms while shaping the next generation of therapies.
We congratulate Dr. Alexander‑Brett on this well‑deserved recognition and celebrate her critical contributions to high‑impact biomedical research.